Items in cart [1] Questions? Call 888-624-8373

PAPERBACK list:$31.75 Web:$28.57 add to cart Rights & Permissions Free PDF Access Free Resources Sign in to download PDF book and chapters PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles The Threat of Pandemic Influenza: Are We Ready? Workshop Summary The Smallpox Vaccination Program: Public Health in an Age of Terrorism Other Related Titles Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program (2008) Board on Population Health and Public Health Practice (BPH) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 113   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix D Meeting Two Agenda Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic Meeting 2 January 7, 2008 Keck Center of The National Academies 500 Fifth Street, NW Room 110 Washington, DC 20001 (live audio/video feed provided in Room 105) 10:00 am Influenza Antivirals and Their Use: Effectiveness, Resistance, Surveillance Alexander Klimov Chief, Virus Surveillance and Diagnosis Branch Influenza Division Centers for Disease Control and Prevention 10:20 am Mathematical Modeling of Resistance in a Pandemic Marc Lipsitch Professor of Epidemiology Department of Epidemiology Department of Immunology and Infectious Diseases Harvard School of Public Health 10:40 am Committee Questions and Discussion Page 113 Front Matter (R1-R10) Summary (1-10) 1 Introduction (11-18) 2 Antiviral Effectiveness, Safety, and Supply (19-38) 3 Ethics, Decision Making, and Communication (39-52) 4 Who Should Get Antivirals and Where? (53-86) References (87-92) Appendix A: Summary of Lessons Learned from Other Mass Distribution Events (93-98) Appendix B: State Plans (99-106) Appendix C: Meeting One Agenda (107-112) Appendix D: Meeting Two Agenda (113-116) Appendix E: Committee Member Biographies (117-122)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 113
Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program Appendix D Meeting Two Agenda Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic Meeting 2 January 7, 2008 Keck Center of The National Academies 500 Fifth Street, NW Room 110 Washington, DC 20001 (live audio/video feed provided in Room 105) 10:00 am Influenza Antivirals and Their Use: Effectiveness, Resistance, Surveillance Alexander Klimov Chief, Virus Surveillance and Diagnosis Branch Influenza Division Centers for Disease Control and Prevention 10:20 am Mathematical Modeling of Resistance in a Pandemic Marc Lipsitch Professor of Epidemiology Department of Epidemiology Department of Immunology and Infectious Diseases Harvard School of Public Health 10:40 am Committee Questions and Discussion

OCR for page 114
Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program 11:00 am Antiviral Distribution Planning: More from State Public Health Agencies Paul Jarris Executive Director Association of State and Territorial Health Officials 11:15 am Committee Questions and Discussion 11:30 am Lessons from Past Public Health Drug or Vaccine Distribution Campaigns: Swine Flu Immunization Program, Vaccine Shortage, Antibiotic Distribution After Anthrax Attacks Swine Flu Walter Dowdle Senior Consultant to World Health Organization Polio Eradication Program Task Force on Child Survival and Development 11:45 am Lunch 12:45 pm Lessons from Past Public Health Drug or Vaccine Distribution Campaigns Influenza Vaccine Shortage Claire Hannan Executive Director Association of Immunization Managers Anthrax Eddy Bresnitz Deputy Health Commissioner State Epidemiologist New Jersey Mary Mahoney Bioterrorism Coordinator North Shore–Long Island Jewish Health System New York 1:30 pm Committee Questions and Discussion

OCR for page 115
Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program 1:50 pm Decision Analysis for Antiviral Distribution Sinan Khan Epidemiology Analyst Los Angeles County Emergency Preparedness and Response Program Telephone and Web-Based Decision Support and Triage Barry Wolcott Associate Professor Uniformed Services University of Health Sciences 2:30 pm Questions from the Committee and Discussion 2:45 pm Break 3:00 pm Antiviral Stockpiling: Stakeholders’ Perspectives Lisa Koonin Associate Director, Business Partnerships Division of Private and Public Partnerships National Center for Health Marketing/CoCHIS Centers for Disease Control and Prevention Antiviral Distribution Planning: The Public–Private-Sector Interface Rex Archer Director Kansas City Health Department Missouri Perspectives from the Private Sector Katherine B. Andrus Assistant General Counsel Air Transport Association of America, Inc. Stephen Jones Cluster Occupational Health Manager Downstream and Chemicals ExxonMobil Corporation Michael McGuire Vice President Roche Laboratories, Inc. 4:00 pm Committee Questions and Discussion

OCR for page 116
Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program 4:15 pm Ethical Principles in Planning for the Distribution of Antiviral Medication Nancy Kass Phoebe R. Berman Professor of Bioethics and Public Health Johns Hopkins University Ethical Framework in Minnesota’s Plans for Distribution of Antiviral Medication Dorothy Vawter Associate Director Center for Health Care Ethics Minnesota 4:45 pm Committee Questions and Discussion 5:00 pm Antiviral Distribution Planning (continued) In a Publicly Funded Health Care System Victoria Davey Deputy Chief, Public Health and Environmental Hazards Officer Veterans Health Administration Department of Veterans Affairs In a Private Health Care System Skip Skivington Vice President of Supply Chain and Director of Operations, Procurement and Supply Program Offices Kaiser Permanente Eric Koscove Chief Emergency Department Kaiser Permanente Medical Center Santa Clara, CA 5:35 pm Committee Questions and Discussion 5:50 pm Public Comment (if time allows) 6:00 pm Adjourn